Barclays PLC Corvus Pharmaceuticals, Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 1 shares of CRVS stock, worth $8. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 1 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$1.08 - $1.92 $14,775 - $26,267	-13,681 Reduced 99.99%	1 $0
Q3 2023 Nov 07, 2023	BUY	$1.41 - $2.97 $19,290 - $40,632	13,681 Added 1368100.0%	13,682 $20,000
Q3 2022 Nov 03, 2022	SELL	$0.71 - $1.17 $6,865 - $11,313	-9,670 Reduced 99.99%	1 $0
Q2 2022 Aug 12, 2022	SELL	$0.87 - $2.03 $1,239 - $2,892	-1,425 Reduced 12.84%	9,671 $10,000
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $725 - $1,232	-497 Reduced 4.29%	11,096 $18,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $27,125 - $61,553	11,592 Added 1159200.0%	11,593 $28,000
Q3 2021 Nov 09, 2021	SELL	$1.89 - $8.53 $5 - $25	-3 Reduced 75.0%	1 $0
Q2 2021 Aug 13, 2021	SELL	$2.46 - $3.14 $1,311 - $1,673	-533 Reduced 99.26%	4 $0
Q1 2021 May 13, 2021	BUY	$2.86 - $4.77 $1,524 - $2,542	533 Added 13325.0%	537 $2,000
Q3 2020 Nov 12, 2020	SELL	$2.6 - $5.37 $5,733 - $11,840	-2,205 Reduced 99.82%	4 $0
Q2 2020 Aug 12, 2020	BUY	$2.01 - $4.05 $4,417 - $8,901	2,198 Added 19981.82%	2,209 $6,000
Q1 2020 May 13, 2020	SELL	$1.74 - $5.98 $20 - $71	-12 Reduced 52.17%	11 $0
Q4 2019 Feb 10, 2020	SELL	$2.56 - $5.44 $135 - $288	-53 Reduced 69.74%	23 $0
Q3 2019 Nov 14, 2019	SELL	$3.01 - $6.5 $40,803 - $88,114	-13,556 Reduced 99.44%	76 $0
Q2 2019 Aug 14, 2019	BUY	$3.3 - $4.58 $31,802 - $44,137	9,637 Added 241.23%	13,632 $51,000
Q1 2019 May 15, 2019	BUY	$3.75 - $4.97 $14,445 - $19,144	3,852 Added 2693.71%	3,995 $16,000
Q4 2018 Feb 14, 2019	SELL	$3.29 - $8.94 $16,900 - $45,924	-5,137 Reduced 97.29%	143 $0
Q3 2018 Nov 14, 2018	BUY	$8.58 - $11.4 $36,550 - $48,564	4,260 Added 417.65%	5,280 $46,000
Q2 2018 Aug 14, 2018	SELL	$9.42 - $13.73 $12,688 - $18,494	-1,347 Reduced 56.91%	1,020 $12,000
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $5,782 - $8,912	773 Added 48.49%	2,367 $27,000
Q4 2017 Feb 14, 2018	BUY	$9.3 - $16.93 $10,546 - $19,198	1,134 Added 246.52%	1,594 $17,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $5,198 - $7,925	460	460 $7,000

Others Institutions Holding CRVS

# of Institutions

Shares Held

28M

Call Options Held

22.9K

Put Options Held

29.8K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $401M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account